Radyoaktif İyot Tedavisi
Özet
Radyoaktif iyot tedavisi (RAIT), iyot-131 (131I) izotopu kullanılarak benign (hipertiroidi, toksik olmayan guatr) ve malign tiroid hastalıklarının tedavisinde 1940'lardan beri güvenle uygulanan oral bir yöntemdir. 131I, hem tanısal görüntülemeye olanak tanıyan gama ışınları hem de tiroid hücrelerinde birikerek doku harabiyeti sağlayan beta ışınları yayar. Benign hastalıklarda amaç hastayı ötiroid duruma getirmek veya bez hacmini küçültmekken; diferansiye tiroid kanserlerinde (DTK) total tiroidektomi sonrası kalan normal tiroid dokusunu ortadan kaldırmak (ablasyon) veya rezeke edilemeyen metastazları tedavi etmek hedeflenir. Tedavinin başarısı; tiroid hacmi, dozu, antitiroid ilaçların kesilme zamanı ve iyot alımı gibi faktörlere bağlıdır. RAIT öncesinde gebelik testi, laboratuvar tetkikleri, sintigrafi ve düşük iyotlu diyet gibi kapsamlı hasta hazırlığı süreçleri kritik öneme sahiptir. Hamilelik ve emzirme kesin kontrendikasyon oluşturmaktadır. Tedavinin en önemli erken yan etkileri arasında sialadenit, radyasyon tiroiditi ve geçici hormon yükselmeleri yer alırken; en belirgin geç yan etkisi kalıcı hipotiroidizmdir. Ayrıca, hedef dışı dokuların radyasyona maruziyetini azaltmak için bol hidrasyon ve limon suyu gibi koruyucu önlemler önerilir.
Radioactive iodine therapy (RAIT), utilizing the iodine-131 (131I) isotope, has been a safe, oral treatment method for benign (hyperthyroidism, toxic non-toxic goiter) and malignant thyroid diseases since the 1940s. 131I emits gamma rays, which allow for diagnostic imaging, and beta rays, which accumulate in thyroid cells via the sodium-iodide symporter to cause localized tissue destruction. In benign conditions, the goal is achieving an euthyroid state or reducing thyroid volume, whereas in differentiated thyroid cancer (DTC), it aims to eliminate residual normal thyroid tissue (ablation) post-thyroidectomy or treat unresectable metastases. Success depends on thyroid volume, administered dose, antitiroid drug discontinuation timing, and dietary iodine intake. Meticulous patient preparation—including pregnancy testing, laboratory panels, scintigraphy, and a low-iodine diet—is vital prior to RAIT. Pregnancy and lactation represent absolute contraindications. Significant early side effects encompass sialadenitis, radiation thyroiditis, and transient hormone spikes, while permanent hypothyroidism constitutes the primary long-term effect. Furthermore, protective measures such as abundant hydration and lemon juice are highly recommended to increase salivary flow and minimize radiation exposure to non-target organs.
Referanslar
Freitas JE. Therapeutic options in the management of toxic and nontoxic nodular goiter. Semin Nucl Med. 2000;30.
Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. J Clin Endocrinol Metab. 1993;76.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19.
Stokkel MPM, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(11):2218-28.
Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24.
Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L. Propylthiouracil before I-131 therapy of hyperthyroid diseases; effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab. 2004;89.
Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial. Thyroid. 2002;12.
Boeleart K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC. Prediction of cure and risk of hypothyroidism in patients receiving I-131 for hyperthyroidism. Clin Endocrinol. 2009;70.
Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338.
Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326.
Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158.
Hall P, Lundell G, Holm LE. Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Copenh). 1993;128.
Reinhardt MJ, Brink I, Joe AY, Mallek D, Ezziddin S, Palmedo H. Radioiodine therapy in Graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med. 2002;29.
Dunkelmann S, Endlicher D, Prillwitz A, Rudolph F, Groth P, Schuemichen C. Results of a TcTUs-optimized radioiodine therapy of multifocal and disseminated functional thyroid autonomy. Nuklearmedizin. 1999;38.
Reinhardt MJ, Joe A, Mallek D, Zimmerlin M, Manka-Waluch A, Palmedo H. Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of 99mTc-pertechnetate thyroid uptake. Eur J Nucl Med Mol Imaging. 2002;29.
Reinhardt M, Kim B, Wissmeyer M, Juengling F, Brockmann H, Mallek D. Dose selection for radioiodine therapy of borderline hyperthyroid patients according to thyroid uptake of 99mTc-pertechnetate: applicability to unifocal thyroid autonomy? Eur J Nucl Med Mol Imaging. 2006;33.
Dietlein M, Dressler J, Eschner W, Lassman M, Leisner B, Reiners C. Procedure guideline for radioiodine test (version 3). Nuklearmedizin. 2007;46.
Pacini F. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153.
Sawka AM. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89.
Hay ID. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26.
Chow SM. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98.
Pelizzo MR. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nuclear medicine communications. 2004;25.
Durante C. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91.
Robbins RJ. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91.
Besic N. The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid. Thyroid. 2003;13.
Hackshaw A. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab. 2007;92.
Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer. 2005;12.
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2008;35(10):1941.
Benua RS. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87.
Freudenberg L, Jentzen W, Goerges R, Petrich T, Marlowe RJ, Knust J, et al. 124I-PET dosimetry in advanced differentiated thyroid cancer. Therapeutic impact. Nuklearmedizin. 2007;46.
Pentlow KS. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37.
Sgouros G. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45.
Krassas GE, Perros P. Thyroid disease and male reproductive function. J Endocrinol Investig. 2003;26.
Ceccarelli C. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab. 2001;86.
